A new survey from Takeda due to be presented at the ESMO Gastrointestinal Cancers Congress in Spain this week highlights ...

Despite the slow trickle of updates on President Donald Trump’s proposed pharmaceutical import tariffs, drugmakers have ...

Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to patients with chronic kidney disease (CKD) who are on dialysis. | Unicycive has ...

The Orphan Cures Act has been added back into the Senate version of President Donald Trump’s “big, beautiful bill” after being ...

Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being canned, ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain ...

UCB’s Fintepla has been approved to treat seizures associated with two epilepsy disorders and now has posted data that could ...

The medtech this week launched a podcast called “Decoded,” in which founder and CEO Jurgi Camblong, Ph.D., will host expert ...

La., has come out critical of Robert F. | Sen. Bill Cassidy, M.D., R-La., has come out critical of Robert F. Kennedy Jr.’s ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...